RNA Formulations with Cationic Polymers for Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current RNA delivery formulations using cationic polymers often result in large polyplex nanoparticles, which can lead to reduced transfection efficacy and increased side effects, and there is a need for improved safety and efficiency in delivering biologically active RNA to target cells.
Innovation Solution
Formulations comprising RNA and cationic polymers where the RNA is predominantly present in monomeric or oligomeric forms, achieved by using a high excess of polymer and forming the compositions at low RNA concentrations, allowing for improved transfection efficacy and reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional cationic polymer formulations are used to deliver RNA, then RNA delivery is achieved, but large polyplex nanoparticles are formed which reduce transfection efficacy and increase side effects
Solution Approach 1:
The patent changes the formulation parameters by using a high excess of cationic polymer (N/P ratio of 10-100) and low RNA concentration (0.01-1 µg/mL), which shifts the RNA distribution from large polyplex nanoparticles to predominantly monomeric and oligomeric forms. This parameter change resolves the contradiction by improving transfection efficacy while reducing side effects associated with large aggregates
Solution Approach 2:
The patent creates different local forms of RNA within the formulation: monomeric, oligomeric, and polyplex nanoparticulate forms. By controlling the formulation conditions, the patent enriches the monomeric and oligomeric forms locally, which have superior transfection properties and lower toxicity compared to large polyplex nanoparticles
2Reliability
If high excess of cationic polymer is used to form formulations, then RNA is predominantly present as monomers and oligomers with improved transfection, but polymer dosage increases
Solution Approach 1:
The patent uses high excess of polymer (N/P ratio 10-100) and low RNA concentration to shift RNA distribution toward monomeric and oligomeric forms. Although this increases polymer quantity, it dramatically improves transfection efficacy, making the increased polymer dosage acceptable for achieving the desired therapeutic effect
3Object-affected harmful factors
If formulations are made at low RNA concentration, then monomeric and oligomeric RNA forms are predominately formed with improved safety, but formulation volume increases
Solution Approach 1:
The patent formulates at low RNA concentrations (0.01-1 µg/mL) to predominantly generate monomeric and oligomeric RNA forms, which have improved safety profiles. The increased formulation volume is acceptable because it enables safer administration with reduced side effect risk while maintaining effective RNA delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new phase of individual RNA molecules in polymer compositions demonstrates superior transfection efficacy, reducing the risk of side effects and enabling effective RNA delivery for applications such as vaccination with improved dose response.
Implementation Method 1
The protonated amines in the polymer can form electrostatic bonds with the anionic charges present in nucleic acids, mainly due to the phosphate back bone present in both DNA and RNA.
Data Source
AI summary
The present invention relates to compositions comprising RNA, preferably messenger RNA (mRNA), more preferably self-amplifying RNA (saRNA), and polymers, in particular cationic polymers, such as polyethylenimine (PEI), poly-L-Lysin (PEL), polyvinylamine (PVA) or polyallylamine (PAA), where individual RNA molecules are present in solution. In the formulations, the RNA is preferentially present in the form of monomers, dimers, timers or oligomers, but not as aggregates comprising a large number of RNA molecules per aggregate, in particular large polyplex nanoparticles. The formulations display improved transfection efficacy and they can be used for delivery of RNA to a subject, where they have an improved dose response relationship in comparison to formulations where large aggregates in the form of polyplex nanoparticles are present.